ReachMD

Be part of the knowledge.™

Clinical Pharmacology

612

LikeLikedUnlike

Episodes 1-15 of 212

- Matt Birnholz, MD
  Peer
- Andrew Little, DO
  Peer
3
Vascular Viewpoints
Understanding the Value of IJ Catheters in Vascular Access Procedures
- Maurice Pickard, MD
  Peer
- Katherine Eban
  Peer
5
Book Club
Bottles of Lies: The Inside Story of the Generic Drug Boom
- Michael B. Bottorff, PharmD, FCCP, FNLA, CLS
  Peer
- Daniel E. Hilleman, PharmD, FCCP
  Peer
12
CME/CE
New Evidence to Improve Management of Patients with or at High Risk of ASCVD ...
- Jennifer Caudle, DO
  Peer
- Kevin Baskin, MD
  Peer
5
Vascular Viewpoints
Decoding HAC Scores: The Impact of Hospital-Acquired Conditions
- Jennifer Caudle, DO
  Peer
- Kevin Baskin, MD
  Peer
6
Vascular Viewpoints
Challenges Faced in Vascular Access Care: A Patient Case
- Mario R. Nacinovich, Jr., MSc
  Peer
- Hildy Schell-Chaple, RN, PhD, CCNS, FAAN
  Peer
12
Vascular Viewpoints
Minimizing Hospital-Acquired Conditions: A Focus on CLABSIs
- Jennifer Caudle, DO
  Peer
- Andre L. Holder, MD, MS
  Peer
- Hildy Schell-Chaple, RN, PhD, CCNS, FAAN
  Peer
- Kevin Baskin, MD
  Peer
7
Vascular Viewpoints
Taking a Multidisciplinary Approach to Vascular Access Care
- Matt Birnholz, MD
  Peer
- Wes Ely, MD, MPH
  Peer
23
Clinician's Roundtable
Delirium: The Hidden Disorder Plaguing ICU Patients
- Robert Mocharnuk, MD
  Peer
- David Kirschner
  Peer
5
CME/CE
Hemophilia A - Making It Personal: A Patient Experience
3
FDA Drug Information Updates
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (L...
- John J. Russell, MD
  Peer
- Meredith Wadman, BM, BCh, M.S.
  Peer
6
Book Club
The Vaccine Race: Science, Politics, & the Human Costs of Defeating Disease
3
FDA Drug Information Updates
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
1
FDA Drug Information Updates
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
1
FDA Drug Information Updates
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
1
FDA Drug Information Updates
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

Loading...

Programs 12/15/19

Segment Chapters

Playlist:

Recommended